Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone

TORONTO and BOSTON, June 21, 2022 /PRNewswire/ — Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE:DNA) ("Ginkgo"), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo's platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC. Access to additional rare cannabinoids will support Cronos' innovation pipeline and commercialization strategy.